Corinne Johnson
Stock Analyst at Goldman Sachs
(4.40)
# 1,239
Out of 5,070 analysts
231
Total ratings
52.9%
Success rate
12.5%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Reiterated: Hold | $33 → $37 | $38.70 | -4.39% | 23 | Jul 16, 2026 | |
| SNDX Syndax Pharmaceuticals | Reiterated: Buy | $34 | $13.25 | +156.60% | 8 | Jul 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $20 → $23 | $28.77 | -20.06% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Reiterated: Sell | $56 → $57 | $124.37 | -54.17% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $158 → $159 | $90.20 | +76.27% | 31 | Jun 14, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Hold | $35 → $36 | $35.36 | +1.81% | 11 | Jun 3, 2026 | |
| TGTX TG Therapeutics | Reiterated: Hold | $41 | $54.53 | -24.81% | 21 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $142.00 | +50.00% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $13.78 | +8.85% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $27 → $25 | $11.81 | +111.69% | 3 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2.5 | $2.30 | +8.70% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $28.59 | +11.93% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $41 | $34.92 | +17.41% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 → $101 | $22.88 | +341.43% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.24 | -19.35% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 → $82 | $61.93 | +32.41% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $53.50 | -40.24% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.85 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.72 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.97 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $5.27 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.77 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $0.6174 | n/a | 1 | Sep 14, 2021 |
Harmony Biosciences Holdings
Jul 16, 2026
Reiterated: Hold
Price Target: $33 → $37
Current: $38.70
Upside: -4.39%
Syndax Pharmaceuticals
Jul 14, 2026
Reiterated: Buy
Price Target: $34
Current: $13.25
Upside: +156.60%
Amylyx Pharmaceuticals
Jun 18, 2026
Reiterated: Buy
Price Target: $20 → $23
Current: $28.77
Upside: -20.06%
Halozyme Therapeutics
Jun 14, 2026
Reiterated: Sell
Price Target: $56 → $57
Current: $124.37
Upside: -54.17%
Rhythm Pharmaceuticals
Jun 14, 2026
Reiterated: Buy
Price Target: $158 → $159
Current: $90.20
Upside: +76.27%
IDEAYA Biosciences
Jun 3, 2026
Reiterated: Hold
Price Target: $35 → $36
Current: $35.36
Upside: +1.81%
TG Therapeutics
Jun 3, 2026
Reiterated: Hold
Price Target: $41
Current: $54.53
Upside: -24.81%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $142.00
Upside: +50.00%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $13.78
Upside: +8.85%
Biohaven
May 28, 2026
Reiterated: Buy
Price Target: $27 → $25
Current: $11.81
Upside: +111.69%
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $2.30
Upside: +8.70%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $28.59
Upside: +11.93%
Apr 15, 2026
Reiterated: Buy
Price Target: $38 → $41
Current: $34.92
Upside: +17.41%
Mar 16, 2026
Reiterated: Buy
Price Target: $102 → $101
Current: $22.88
Upside: +341.43%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.24
Upside: -19.35%
Jan 12, 2026
Reiterated: Buy
Price Target: $56 → $82
Current: $61.93
Upside: +32.41%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $53.50
Upside: -40.24%
Jul 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $18.85
Upside: n/a
Jul 31, 2024
Reiterated: Buy
Price Target: n/a
Current: $3.72
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.97
Upside: n/a
Jun 18, 2024
Reiterated: Hold
Price Target: n/a
Current: $5.27
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $3.77
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $0.6174
Upside: n/a